Dr. Rohde has extensive experience developing mRNA technologies and technologies for high-throughput and high-content screening. His work is described in numerous peer-reviewed publications, and has been covered by Technology Review, Nature, Bioscience Magazine, Analytical Chemistry, The Economist, and many others. Dr. Rohde is currently leading Factor’s efforts to apply our RiboSlice™ gene-editing technology, and FactorStem™ cell-reprogramming and differentiation technologies to the development of new research models, including high-throughput screening-compatible human cell libraries, for the study and treatment of Alzheimer’s disease.
This person is not in the org chart
This person is not in any offices